Phaseline

Companies › Lakefront Biotherapeutics West

Lakefront Biotherapeutics West: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Hematology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OM336
Bispecific antibody targeting BCMA and CD3
BCMA, CD3Phase 1AIHA - Warm Autoimmune Hemolytic Anemia; Sjogrens DiseaseDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07083960OM336Phase 1AIHA - Warm Autoimmune Hemolytic AnemiaHematologyDec 2026
NCT07229144OM336Phase 1Sjogrens DiseaseImmunologyJun 2027

Targets

BCMA (1) CD3 (1)

Companies with the same targets

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Kali Therapeutics Johnson & Johnson (Janssen) AstraZeneca iCell Gene Therapeutics AbbVie Chongqing Precision Biotech Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Excyte Biopharma Vironexis Biotherapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.